Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017

Kamada (Nasdaq:KMDA) a plasma-derived protein therapeutics company focused on orphan indications, today announced financial results for the three and 12-months ended December 31, 2017.

As quoted in the press release:

“Kamada’s financial performance for full-year 2017 was strong, highlighted by the achievement of revenue growth of 33 percent,” said Amir London, Kamada’s Chief Executive Officer. “Importantly, our total revenue of $102.8 million, which exceeded our previously provided guidance of $100 million in 2017 represented the highest annual revenue for Kamada since the company was founded. Driven primarily by increased sales of GLASSIA, full-year 2017 revenues from the Proprietary Products segment were $79.5 million, a substantial 42 percent increase year-over-year, and higher than our initial forecast of $76 to $78 million.   Kamada also generated positive operating and net income for the full-year 2017, and gross profit grew 50 percent year-over-year. Additionally, during 2017, we also generated $3.9 million in cash flow from operating activities.”

Click here to read the full press release.